CA2446161A1 - Methode de traitement du diabete - Google Patents

Methode de traitement du diabete Download PDF

Info

Publication number
CA2446161A1
CA2446161A1 CA002446161A CA2446161A CA2446161A1 CA 2446161 A1 CA2446161 A1 CA 2446161A1 CA 002446161 A CA002446161 A CA 002446161A CA 2446161 A CA2446161 A CA 2446161A CA 2446161 A1 CA2446161 A1 CA 2446161A1
Authority
CA
Canada
Prior art keywords
phenyl
formula
alkyl
ethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002446161A
Other languages
English (en)
Inventor
Emanuele Sher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2446161A1 publication Critical patent/CA2446161A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une méthode de traitement du diabète consistant à administrer à un patient une dose efficace d'un potentialisateur approprié du récepteur AMPA.
CA002446161A 2001-05-04 2002-04-22 Methode de traitement du diabete Abandoned CA2446161A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28889101P 2001-05-04 2001-05-04
US60/288,891 2001-05-04
PCT/US2002/011847 WO2002089848A2 (fr) 2001-05-04 2002-04-22 Methode de traitement du diabete

Publications (1)

Publication Number Publication Date
CA2446161A1 true CA2446161A1 (fr) 2002-11-14

Family

ID=23109101

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002446161A Abandoned CA2446161A1 (fr) 2001-05-04 2002-04-22 Methode de traitement du diabete

Country Status (5)

Country Link
EP (1) EP1390072A2 (fr)
JP (1) JP2004530680A (fr)
AU (1) AU2002307327A1 (fr)
CA (1) CA2446161A1 (fr)
WO (1) WO2002089848A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5014334B2 (ja) * 2005-10-06 2012-08-29 イーライ リリー アンド カンパニー Ａｍｐａ受容体増強剤
DE102008047461A1 (de) * 2008-09-17 2010-04-15 Dr.Ing.H.C.F.Porsche Aktiengesellschaft Verbindungseinrichtung zum Verbinden von Verkleidungselementen
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
BR112015031249A2 (pt) * 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
US10882837B2 (en) * 2017-01-24 2021-01-05 Alphala Co., Ltd. Amide compounds and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2703051B1 (fr) * 1993-03-26 1995-04-28 Adir Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
PE20000943A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de sulfonamida
AU5239999A (en) * 1998-07-31 2000-02-21 Eli Lilly And Company Heterocyclyl sulphonamide derivatives
BR0010183A (pt) * 1999-04-30 2002-01-08 Lilly Co Eli Derivados de monofluoroalquila
EP1246797B1 (fr) * 1999-12-08 2008-07-23 Eli Lilly And Company Derives de sulfonamide de cyclopentyle
WO2001089510A2 (fr) * 2000-05-24 2001-11-29 Eli Lilly And Company Methode de traitement de l'obesite

Also Published As

Publication number Publication date
EP1390072A2 (fr) 2004-02-25
WO2002089848A3 (fr) 2002-12-12
AU2002307327A1 (en) 2002-11-18
WO2002089848A2 (fr) 2002-11-14
JP2004530680A (ja) 2004-10-07

Similar Documents

Publication Publication Date Title
CA2338916A1 (fr) Derives d'amide, de carbamate et d'uree
EP1183232B1 (fr) Derives de monofluoralkyle
CA2338994A1 (fr) Derives de sulfonamide
US6900353B2 (en) Cyclopentyl sulfonamide derivatives
CA2338864A1 (fr) Derives de sulfamide
US6911476B2 (en) Sulfonamide derivatives
EP1395550B1 (fr) Derives de cycloalcenylsulfonamide
US6515026B2 (en) Sulphonamide derivatives
CA2446161A1 (fr) Methode de traitement du diabete
US6552086B1 (en) Sulfonamide derivatives
CA2338862A1 (fr) Alcenyle-sulfamides
EP1330233B1 (fr) Procede relatif au traitement de l'accident vasculaire cerebral
US20040063680A1 (en) Method of treating stroke

Legal Events

Date Code Title Description
FZDE Dead